Search research articles
Contact Us
Filters
Showing results (1-10 of 112) with videos related to
Page
of 12
Sort By:
Clinical Therapeutics
|
September 24, 2013
Targeted therapy in chronic lymphocytic leukemia: past, present, and future
Alexey V Danilov
British Journal of Haematology
|
November 20, 2020
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies
Alexey V Danilov, Daniel O Persky
Therapeutic Advances in Hematology
|
April 2, 2021
The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia
Max J Gordon, Alexey V Danilov
Current Oncology Reports
|
April 14, 2022
CAR T-Cell Therapy in the Older Person: Indications and Risks
Geoffrey Shouse, Alexey V Danilov, Andy Artz
Expert Review of Anticancer Therapy
|
January 27, 2021
Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy
Liana Nikolaenko, Tingting Liu, Alexey V Danilov
Oncotarget
|
October 22, 2021
Neddylation and anti-tumor immunity
Xiaoguang Wang, Scott Best, Alexey V Danilov
Current Hematologic Malignancy Reports
|
May 4, 2019
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL
Adam S Kittai, Matthew Lunning, Alexey V Danilov
The Journal of Biological Chemistry
|
April 30, 2014
Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress
Ryan S Soderquist, Alexey V Danilov, Alan Eastman
Current Hematologic Malignancy Reports
|
January 28, 2021
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents
Edward Nabrinsky, Alexey V Danilov, Paul B Koller
The Oncologist
|
March 19, 2022
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
Alexey V Danilov, Massimo Magagnoli, Matthew J Matasar
Page
of 12
Search research articles
Search
Showing results (1-10 of 112) with videos related to
Sort By:
Page
of 12
Clinical Therapeutics
|
September 24, 2013
Targeted therapy in chronic lymphocytic leukemia: past, present, and future
Alexey V Danilov
British Journal of Haematology
|
November 20, 2020
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies
Alexey V Danilov, Daniel O Persky
Therapeutic Advances in Hematology
|
April 2, 2021
The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia
Max J Gordon, Alexey V Danilov
Current Oncology Reports
|
April 14, 2022
CAR T-Cell Therapy in the Older Person: Indications and Risks
Geoffrey Shouse, Alexey V Danilov, Andy Artz
Expert Review of Anticancer Therapy
|
January 27, 2021
Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy
Liana Nikolaenko, Tingting Liu, Alexey V Danilov
Oncotarget
|
October 22, 2021
Neddylation and anti-tumor immunity
Xiaoguang Wang, Scott Best, Alexey V Danilov
Current Hematologic Malignancy Reports
|
May 4, 2019
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL
Adam S Kittai, Matthew Lunning, Alexey V Danilov
The Journal of Biological Chemistry
|
April 30, 2014
Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress
Ryan S Soderquist, Alexey V Danilov, Alan Eastman
Current Hematologic Malignancy Reports
|
January 28, 2021
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents
Edward Nabrinsky, Alexey V Danilov, Paul B Koller
The Oncologist
|
March 19, 2022
Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment
Alexey V Danilov, Massimo Magagnoli, Matthew J Matasar
Page
of 12